LOGO
LOGO

Fulgent Q1 Core Revenue Rises 16% To $73.5M, Company Reiterates 2025 Outlook

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Fulgent Genetics, Inc. (FLGT), a technology-driven precision medicine company, reported solid financial results for the first quarter of 2025, with strong performance in its core laboratory services business and continued investment in its therapeutic pipeline.

The California-based company provides advanced laboratory testing services and is developing targeted cancer therapies through its proprietary nanoencapsulation platform.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.